U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412171) titled 'NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC' on Jan. 21.
Brief Summary: The NECTAR study is a multicenter, open-label, randomized phase II clinical trial designed to evaluate a neoadjuvant treatment strategy in patients with localized upper tract urothelial carcinoma (UTUC).
In this study, eligible participants will be randomly assigned to receive either neoadjuvant treatment with toripalimab plus the investigational drug 9MW2821 followed by radical nephroureterectomy with or without lymph node dissection, or upfront radical nephroureterectomy with or without lymph node dissection as standard of care. The purpose...